Poor
Mostly Aligned
Patient Risk:
Low
Summary
The AI response provided an assessment of a thyroid C-cell tumor risk claim, but it did not evaluate the specific excipient/ingredient claims submitted. The only substantive label alignment addressed (thyroid C-cell tumor risk) is not the same as the claims about excipients; therefore, most of the provided claims are unsupported by the supplied label excerpts and the response does not demonstrate label-based support for them.
Category Scores
Accurate Statements
Semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents, and the label states it is unknown whether this translates to humans.
FDA label excerpts: Section 5.1 and Boxed Warning.
OZEMPIC is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
FDA label excerpts: Section 4 and Section 5.1 (also Boxed Warning).
Routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection, and elevated calcitonin should prompt further evaluation (where measured).
FDA label excerpt: Section 5.1.
Unsupported Statements
Ozempic contains inactive ingredients (excipients) in addition to semaglutide.
No excipient/ingredient list information is provided in the supplied label excerpts.
The exact inactive ingredient list for Ozempic is provided in the product’s labeling.
Not supported by the supplied prescribing information excerpts (which do not include an excipient list).
Ozempic includes semaglutide plus excipients used for solubility and stability in the injectable solution.
Not supported by the supplied label excerpts.
The specific excipients in Ozempic can vary by presentation and labeling version.
Not supported by the supplied label excerpts.
The full ingredient list for Ozempic can be verified using the FDA label or prescribing information for the specific product.
While generally plausible, it is not supported by the supplied label excerpts provided to this audit.
Contradictions
Important Omissions
Evaluation of the submitted excipient/ingredient claims against label sections that contain inactive ingredient/excipient listing (or an explicit statement in the provided label excerpts).
Importance:
Moderate
The response did not explicitly address the accuracy of any excipient-specific statements (inactive ingredient presence, exact list availability, solubility/stability purposes, or variability by presentation/version) using the provided labeling text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clearly label-aligned statements in the provided response relate to boxed warning/contraindications and thyroid C-cell tumor risk counseling; however, the excipient-related claims were not supported by the provided label excerpts, limiting the reliability of those specific assertions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
The response evaluated a thyroid C-cell tumor risk claim but did not support the excipient/ingredient claims with the supplied prescribing information excerpts; as a result, most submitted claims remain unsupported.
Suggested Improvement
Restrict evaluation to the exact claims provided and cite the specific label sections that list inactive ingredients/excipients (or explicitly note that such information is not contained in the supplied excerpts). If excipient details are not present, mark those claims as unsupported.